Darrell E. White, MD, is the founder of Skyvision Centers in Ohio. His blog for Ocular Surgery News will focus on issues related to dry eye disease.

BLOG: Amazon PillPack: A solution to price gouging?

July 16, 2019

Cruising along Interstate 77, employing my Google-Fu and doing background research for a patent application (I’m a scientist! Who knew?!), I had an epiphany about…

BLOG: Allergan answers the market

July 1, 2019

What in heavens is happening in eye care pharma? Allergan was just sold to one-trick pony AbbVie, maker of Humira, in the same 12-month period that Shire’s eye…

BLOG: Is fluorometholone the magic mucin medicine?

June 25, 2019

Well now, what have we here? For years DED docs have lamented the absence of a medication that in some way improves the mucin part of tears. There has been lots of…

BLOG: Alcon, er, Novartis takes out Shire

May 10, 2019

For those of you keeping score at home, make this one a win for White the prognosticator. In my annual September column on anti-inflammatory meds in dry eye disease, my…

BLOG: A way to look at leadership

May 2, 2019

Twice a year I travel for my day job to a large trade show dedicated to a combination of continuing education and commerce. Part of what I do when I am attending these…

BLOG: Dissecting DREAM Part 4: Why all the fuss?

April 25, 2019

Boy, has there been a lot of noise about the DREAM study, or what?! I mean, come ON! We’re talking about fish oil here. Not some life-saving treatment that took…

BLOG: Dissecting DREAM, part 3: Wanted: an effective placebo

April 17, 2019

Placebo: a substance or treatment of no intended therapeutic value. It can be made to resemble an active treatment or substance so that it functions as a control in…

BLOG: Dissecting DREAM, part 2: Masked, prospective chaos

April 3, 2019

DREAM has been touted in numerous press releases as a randomized, controlled, masked prospective trial to investigate whether fish oil is effective in treating the…

BLOG: CVS stands down in Walmart pharmacy battle

March 6, 2019

Remember part 1 of my series on why our medicines are so expensive for our patients? If you take the “way back machine” to the days before pharmacy benefit…

BLOG: MGD heats up: J&J lowers LipiFlow cost

February 18, 2019

Some 5 years after I first made the suggestion, the new owners of the TearScience suite of meibomian gland dysfunction treatments — LipiView, LipiScan, LipiFlow…